What medicine is Imdelltra (Tarlatamab-dlle)?

Imdelltra (Tarlatamab-dlle) is a first-in-class bispecific delta-like ligand 3 (DLL3)-directed CD3 T cell engager indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed during or after platinum-based chemotherapy. Imdelltra received accelerated approval based on encouraging response rates and duration of response (DOR) observed in clinical studies. Continued approval for this indication may be contingent upon verification and characterization of clinical benefit in confirmatory trials.

Small cell lung cancer(SCLC) is an aggressive lung cancer that is closely related to smoking. DLL3 is a protein expressed on the surface of small cell lung cancer cells in approximately 85-96% of patients with small cell lung cancer, but is rarely expressed on healthy cells. Imdelltra is a targeted therapy that binds DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells. This results in the formation of cytolytic synapses as cancer cells lyse.

Imdelltra is administered by intravenous infusion, and the administration time exceeds 1 hour. The specific dosage and method should be determined by professional medical personnel. Imdelltra comes with a boxed warning for cytokine release syndrome and neurotoxicity, including immune effector cell-associated neurotoxicity syndrome [ICANS]. Common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea.